1. Home
  2. SCYX vs TLIH Comparison

SCYX vs TLIH Comparison

Compare SCYX & TLIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • TLIH
  • Stock Information
  • Founded
  • SCYX 1999
  • TLIH 1998
  • Country
  • SCYX United States
  • TLIH Singapore
  • Employees
  • SCYX N/A
  • TLIH N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • TLIH
  • Sector
  • SCYX Health Care
  • TLIH
  • Exchange
  • SCYX Nasdaq
  • TLIH Nasdaq
  • Market Cap
  • SCYX 26.6M
  • TLIH 29.1M
  • IPO Year
  • SCYX 2014
  • TLIH 2025
  • Fundamental
  • Price
  • SCYX $0.88
  • TLIH $0.59
  • Analyst Decision
  • SCYX
  • TLIH
  • Analyst Count
  • SCYX 0
  • TLIH 0
  • Target Price
  • SCYX N/A
  • TLIH N/A
  • AVG Volume (30 Days)
  • SCYX 212.7K
  • TLIH 1.2M
  • Earning Date
  • SCYX 08-19-2025
  • TLIH 01-01-0001
  • Dividend Yield
  • SCYX N/A
  • TLIH N/A
  • EPS Growth
  • SCYX N/A
  • TLIH N/A
  • EPS
  • SCYX N/A
  • TLIH 0.05
  • Revenue
  • SCYX $2,630,000.00
  • TLIH $42,862,063.00
  • Revenue This Year
  • SCYX $410.22
  • TLIH N/A
  • Revenue Next Year
  • SCYX $248.83
  • TLIH N/A
  • P/E Ratio
  • SCYX N/A
  • TLIH $12.59
  • Revenue Growth
  • SCYX N/A
  • TLIH N/A
  • 52 Week Low
  • SCYX $0.66
  • TLIH $0.55
  • 52 Week High
  • SCYX $1.82
  • TLIH $7.00
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 68.89
  • TLIH N/A
  • Support Level
  • SCYX $0.68
  • TLIH N/A
  • Resistance Level
  • SCYX $0.92
  • TLIH N/A
  • Average True Range (ATR)
  • SCYX 0.04
  • TLIH 0.00
  • MACD
  • SCYX 0.02
  • TLIH 0.00
  • Stochastic Oscillator
  • SCYX 83.33
  • TLIH 0.00

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About TLIH Ten-League International Holdings Limited Ordinary Shares

Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental and provision of engineering consultancy services to port, construction, civil engineering and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment and port machinery. The company operates in Singapore and Other International Countries.

Share on Social Networks: